PharmaBlock Sciences (Nanjing), Inc. Stock Price

PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, DNA encoded library technology, and mega virtual library screening to support the discovery of novel hit compounds; custom synthesis (FFS); and full time equivalent (FTE). The company also provides small molecule drug substance CDMO services, including optimal route scouting; FFS and FTE for process research and development of RSMs, intermediates, and APIs; impurity studies and synthesis; solid state chemistry; analytical development and quality control; cGMP manufacturing of intermediates and APIs; and CMC regulatory filing support. In addition, it offers small molecule DP CDMO services, such as candidate screening and selection, early development, full development, registration, and post-approval; and new modality services, including target protein degrader, peptide, oligonucleotide, and ADC services. PharmaBlock Sciences (Nanjing), Inc. was founded in 2006 and is based in Nanjing, the People's Republic of China.